Biotech | July 16, 2022
Enveric Biosciences advances drug development for mental health indications
Advancing to IND-enabling studies with multiple drug candidates
Advancing to IND-enabling studies with multiple drug candidates
Becomes first Japanese logistics company to collaborate with EMBALL’ISO, which has a proven track record in vaccine transport
The centres will be located in Tier I and Tier II cities
The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines
The company claims that this is the first time a mental wellness start-up has gone phygital in a Tier 2 city
The sNDA was supported by the clinical results from cohort B of a single-arm, multi-center, pivotal study (RELIANCE study) on Carteyva in adult patients with relapsed or refractory B cell non-hodgkin lymphoma in China
US $ 555,000 invested by Wavemaker Partners in pre-seed round
The supplemental adolescent approval enhances Solosec’s strong position as the first and only single-dose oral prescription antimicrobial agent approved for the treatment of both trichomoniasis and BV
Application based on the pivotal Phase 3 TRANSFORM study in which Breyanzi showed significant and clinically meaningful improvements over salvage chemotherapy followed by high-dose chemotherapy plus autologous stem cell transplant, which has been the standard of care for more than 20 years
Rapid testing produces air sample results in 30 minutes
Subscribe To Our Newsletter & Stay Updated
